RALEIGH, North Carolina — December 15, 2025 — Sprout Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Addyi® (flibanserin 100 mg) for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women under 65 years of age, marking a historic first in women’s sexual health. The decision expands Addyi’s original 2015 approval for premenopausal women and closes a long-standing treatment gap for millions of postmenopausal women experiencing distressing low sexual desire. The approval follows an FDA Priority Review, underscoring the agency’s recognition of a significant unmet medical need and reinforcing the role of evidence-based pharmacotherapy in women’s health.
Science Significance
From a scientific standpoint, the expanded approval of Addyi® validates more than a decade of clinical research into the neurobiological underpinnings of sexual desire. Flibanserin is a non-hormonal therapy that modulates key neurotransmitters involved in sexual response, differentiating it from endocrine-based approaches. Clinical data supporting the approval demonstrate that Addyi provides clinically meaningful improvement in sexual desire and associated distress, reaffirming its established safety and efficacy profile across broader patient populations. As the largest and most rigorous clinical trial program conducted in women’s sexual health to date, the Addyi development program represents a scientifically important step toward normalizing and rigorously studying conditions historically underrepresented in clinical research.
Regulatory Significance
The FDA’s decision represents a major regulatory milestone in gender-equitable drug development. The expanded indication followed a Priority Review designation, reserved for therapies that offer meaningful improvement for serious or underserved conditions. Approval required comprehensive evaluation of clinical efficacy, safety monitoring, labeling, and post-marketing risk mitigation, including adherence to stringent cGMP manufacturing and pharmacovigilance standards. For the cGxP community, this approval highlights the FDA’s evolving regulatory approach to women’s health, recognizing validated endpoints and patient-reported outcomes as critical components of regulatory decision-making while maintaining rigorous compliance expectations.
Business Significance
Advertisement
Commercially, the expanded approval significantly strengthens Sprout Pharmaceuticals’ market position and extends the lifecycle of Addyi®, the #1 prescribed treatment for HSDD. By including postmenopausal women, the addressable patient population expands substantially, creating new growth opportunities while reinforcing Sprout’s strategic focus on underserved therapeutic areas. The approval also enhances the company’s ability to engage healthcare providers, payers, and advocacy organizations with a broader, FDA-endorsed indication, supporting long-term brand value and market sustainability in a competitive pharmaceutical landscape.
Patients’ Significance
For patients, the impact is transformative. Until now, postmenopausal women with HSDD had no FDA-approved pharmacological option, despite the condition being common, distressing, and associated with diminished quality of life. The approval of Addyi offers validated, science-backed treatment for women who have long felt overlooked by the healthcare system. By formally recognizing sexual desire as an important aspect of overall wellbeing at every life stage, the decision empowers patients and clinicians to engage in informed, evidence-based discussions and pursue treatment without stigma.
Policy Significance
At a policy level, the FDA’s approval signals a broader commitment to addressing systemic gaps in women’s health research and treatment access. HSDD affects a substantial proportion of women, yet has historically received limited regulatory and funding attention. This decision reinforces the importance of inclusive clinical development, patient-centered endpoints, and regulatory frameworks that reflect real-world health burdens. The approval may also influence future policy discussions around research prioritization, guideline updates, and insurance coverage for women’s sexual health therapies.
The FDA approval of Addyi® (flibanserin) for postmenopausal women with HSDD represents a landmark achievement at the intersection of science, regulation, and patient advocacy. By expanding access to a proven, non-hormonal therapy, the decision affirms that women’s sexual health deserves the same rigor, respect, and regulatory attention as any other medical condition. For the cGxP.wire audience, this milestone underscores how robust clinical evidence, sustained regulatory engagement, and quality-driven development can reshape standards of care and advance equity across the pharmaceutical landscape.
Source: Sprout Pharmaceuticals press release
